Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)

Next Previous
Search
Trial Profile

A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maveropepimut-S (Primary) ; Pembrolizumab (Primary) ; Cyclophosphamide
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms VITALIZE
  • Sponsors IMV

    • Most Recent Events

    • 13 Sep 2024 This trial has been Discontinued in Hungary (End date: 2023-03-31) according to European Clinical Trials Database record.
    • 12 Sep 2023 This trial has been completed in Poland (End Date: 31 Aug 2023), according to European Clinical Trials Database record.
    • 01 May 2023 According to IMV media release, the company expects that it will have sufficient funds to complete its CCAA proceedings and potential restructuring. The company's Dartmouth, Nova Scotia headquarters and laboratories remain open in a limited capacity and its clinical trials, including this study will pause enrollment, pending the outcome of the review of strategic alternatives.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top